Welcome to our dedicated page for FSD Pharma Class B Subordinate Voting Shares news (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares stock.
FSD Pharma Inc. (HUGE) is a biopharmaceutical innovator advancing cannabinoid-based therapies and pharmaceutical-grade cannabis production. This news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering clinical trial progress for neurodegenerative treatments, product commercialization efforts including alcohol misuse solutions, and research collaborations shaping the future of medical cannabis. Our curated updates ensure you stay informed about developments impacting FSD Pharma's position in biotech innovation.
Key coverage areas: Phase trial results for Lucid-MS multiple sclerosis treatment, unbuzzd™ market expansion, intellectual property updates, and manufacturing capacity enhancements. All content is verified through primary sources to maintain accuracy.
Bookmark this page for centralized access to FSD Pharma's latest announcements, analyst commentary, and progress reports on therapies targeting autoimmune disorders and neurological conditions.
FSD Pharma Inc. (NASDAQ: HUGE) has established a Regulatory Advisory Board to oversee its clinical drug development. The board includes experts Dr. Joga Gobburu and Dr. Mary Melnyk, who bring extensive experience from the FDA and various pharmaceutical companies. Dr. Gobburu has a notable background in pharmacometrics, contributing to numerous FDA drug approvals, while Dr. Melnyk has expertise in regulatory compliance for drug and device development. This strategic move aims to enhance FSD Pharma's capacity to advance its drug candidates in neurology and inflammation.
FSD Pharma Inc. (NASDAQ: HUGE) announced that Interim CEO Anthony Durkacz will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference on December 6, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET via the investor relations section of FSD's website. Additionally, FSD Pharma's management team will hold one-on-one investor meetings during the conference. The company focuses on developing innovative drug candidates, including ultra-micronized palmitoyl ethylamine (FSD-PEA) and other compounds for mental and neurodegenerative disorders.
FSD Pharma Inc. (NASDAQ: HUGE) announced pre-clinical data supporting Lucid-MS, its lead drug candidate for multiple sclerosis treatment. The study showed that mice treated with Lucid-MS improved significantly in clinical scores compared to the placebo. The results suggest that Lucid-MS may prevent myelin degradation and encourage functional recovery. CEO Dr. Lakshmi P. Kotra emphasized the drug's unique therapeutic potential and expressed eagerness to advance it to clinical trials. FSD Pharma is also developing other candidates like Lucid-PSYCH for mental health disorders.
FSD Pharma has appointed Dr. Eleanor N. Fish, an expert in immunology and inflammatory disorders, to its Research and Clinical Advisory Board. Dr. Fish joins the firm to enhance the development of FSD-PEA, an anti-inflammatory agent, and Lucid-MS, aimed at treating multiple sclerosis. Her extensive experience, including her role on the Government of Canada’s Expert Scientific Panel, is expected to drive the company’s research and clinical initiatives forward.
FSD Pharma Inc. (NASDAQ: HUGE) has partnered with Covar Pharmaceuticals Inc. to produce research quantities of its drug candidate, Lucid-PSYCH, for clinical evaluation. This psychoactive compound aims to treat major depressive disorders and is supported by machine learning analysis of its properties. Under the agreement, Covar will manufacture both Non-GMP and GMP versions of Lucid-PSYCH for preclinical and Phase 1 clinical trials. The initiative is part of FSD's strategy to move Lucid-PSYCH from research to clinical application, with expectations of IND approval.
FSD Pharma, a life sciences holding company, announced participation in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Interim CEO Anthony Durkacz and Lucid Psycheceuticals CEO Dr. Lakshmi P. Kotra will present live on October 13 at 2:30 p.m. ET. Investors can register for the event here. FSD Pharma focuses on innovative healthcare solutions and is actively pursuing acquisitions in the biotech space, particularly targeting mental health disorders and neurodegenerative diseases.
FSD Pharma Inc. (NASDAQ: HUGE) has engaged several firms including Hybrid Financial Ltd., North Equities Corp., and Looking Glass Capital Consultants to enhance market awareness and shareholder communication. The contracts involve monthly fees and the issuance of common shares as compensation, totaling approximately US$22,500 to US$50,000 per month. Integral Wealth Securities Limited has also been retained for market-making services to improve liquidity. These efforts signify a strategic allocation of resources toward investor relations following a review of capital on hand.
FSD Pharma Inc. has successfully acquired Lucid Psycheceuticals Inc. for approximately
FSD Pharma (HUGE) announced a definitive agreement to acquire Lucid Psycheceuticals for approximately US$9 million in FSD stock. The acquisition aims to bolster FSD's pipeline in psychedelics and medical cannabis, specifically targeting neurodegenerative diseases and mental health disorders. Lucid brings a strong pipeline of therapeutic compounds and is partnered with the University Health Network for exclusive rights to new chemical entities. The transaction involves the issuance of approximately 4.5 million FSD Shares and requires shareholder approval.
FSD Pharma Inc. (NASDAQ:HUGE) has announced the termination of its Phase 2 clinical trial for FSD-201, designed to treat COVID-19, after an independent review indicated its commercial viability was unlikely. Following the FDA's approval of the IND in June 2020 and the Phase 2 study in September 2020, the company has opted to refocus resources on more viable opportunities. Despite the disappointment over discontinuing the trial, FSD Pharma remains committed to exploring other commercial avenues for FSD-201, as stated by President Zeeshan Saeed.
